Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cytodyn Inc (OP:CYDY)

0.3395 +0.0055 (+1.65%)
Streaming Delayed Price Updated: 10:51 AM EST, Nov 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cytodyn Inc

< Previous 1 2 3 4 5 Next >
News headline image
CytoDyn Announces Leadership Transition Plan to Support Regulatory Approval and Commercialization of Leronlimab
From CytoDyn Inc.
Via Business Wire
News headline image
CytoDyn Cancels Webcast and Live Q/A Scheduled for Today
From CytoDyn Inc.
Via Business Wire
News headline image
Published Paper Indicates Leronlimab Shows Activity Against 4-Class Drug Resistant HIV-1 From Heavily Treatment Experienced (“HTE") Subjects
From CytoDyn Inc.
Via Business Wire
News headline image
Leronlimab 14-Week, NASH Clinical Trial Met Primary Endpoint (PDFF) and Secondary Endpoint (cT1) for Per Protocol Population in 350 mg Weekly Dose
From CytoDyn Inc.
Via Business Wire
News headline image
Two Paths to End the Pandemic but the Hybrid Approach Looks Dominant ↗
Pfizer (NYSE: PFE) is arguably one of the biggest leaders in COVID-19 technology, whether it’s their vaccine or their newly approved oral antiviral called Paxlovid. The... 
Via Benzinga
News headline image
CytoDyn Announces Favorable Ruling Granting Injunction Against Former CRO
From CytoDyn Inc.
Via Business Wire
News headline image
CytoDyn Receives Positive Response From FDA in Regard to its Phase 3, Registrational Trial in COVID-19 Critically Ill Population
From CytoDyn Inc.
Via Business Wire
News headline image
NASH Phase 2 Trial Open-Label Portion Demonstrates Average 80 msec cT1 Reduction in 50% of Patients and Reduction of Nearly 50 msec in 80% of Patients
From CytoDyn Inc.
Via Business Wire
News headline image
CytoDyn Submits Protocol with the FDA for Phase 3 Registrational Trial of Leronlimab for Critically Ill COVID-19 Population
From CytoDyn Inc.
Via Business Wire
News headline image
CytoDyn Files for Expanded Access Use of Leronlimab for Multi-Drug Resistance HIV Patients
From CytoDyn Inc.
Via Business Wire
News headline image
CytoDyn’s CRO in Brazil Met with ANVISA to Modify CD16 Trial for Critically Ill COVID-19 Patients to Expedite Interim Analysis After 51 Patients, Potentially in 1Q2022
From CytoDyn Inc.
Via Business Wire
News headline image
CytoDyn Submits CMC (Manufacturing) Section of HIV BLA to FDA Under Previously Authorized Rolling Review; Last (Clinical) Section Will Complete Full BLA Submission
From CytoDyn Inc.
Via Business Wire
News headline image
CytoDyn’s Chairman, CMO, and Head of Business Development Dr. Scott A. Kelly to Present at World Antiviral Congress 2021 Beginning Tomorrow
From CytoDyn Inc.
Via Business Wire
News headline image
Leronlimab (350 mg) Weekly Use for 14 Weeks in Open Label Arm of NASH Trial Produces Fibrosis Reduction as High as 93 msec Amongst First 15 Patients with Average Reduction of 24 msec
From CytoDyn Inc.
Via Business Wire
News headline image
CytoDyn Research Paper on Leronlimab Published in Frontiers in Immunology Journal
From CytoDyn Inc.
Via Business Wire
News headline image
Health Canada Authorizes Emergency Use of Leronlimab for Treatment of First Triple-Negative Breast Cancer Patient in Canada
From CytoDyn Inc.
Via Business Wire
News headline image
CytoDyn Inc. Announces Adjournment of Annual Meeting of Shareholders to November 24, 2021 Due to Lack of Quorum
From CytoDyn Inc.
Via Business Wire
News headline image
CytoDyn Announces Delaware Court Has Denied Activist Group’s Motion to Prevent Annual Meeting from Taking Place
From CytoDyn Inc.
Via Business Wire
News headline image
CytoDyn Alerts Shareholders to Vote on Company’s Proxy Card Ahead of October 28th Annual Meeting
From CytoDyn Inc.
Via Business Wire
News headline image
Group of CytoDyn Stockholders Comments on Delaware Court Decision
From Gasthalter & Co. on behalf of CytoDyn Inc. shareholders
Via Business Wire
News headline image
Delaware Court Agrees with CytoDyn that Activist Group’s Nominations are Invalid
From CytoDyn Inc.
Via Business Wire
News headline image
These OTC Markets Securities had the Most Trading Activity in September ↗
Photo by Annie Spratt on Unsplash As the 3rd quarter came to a close in September, the OTC Markets saw a slight decrease in total trading volume even as companies reported... 
Via Benzinga
News headline image
CytoDyn Comments on Rosenbaum/Patterson Activist Group “Plan”
From CytoDyn Inc.
Via Business Wire
News headline image
Group of CytoDyn Stockholders Releases White Paper Regarding Company’s Extremely Unfavorable Borrowing Practices
From Gasthalter & Co. on behalf of CytoDyn Inc. shareholders
Via Business Wire
News headline image
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6) Enanta Pharmaceuticals, Inc... 
Via Benzinga
News headline image
CytoDyn to Present at Emerging Growth Conference on September 29 Followed by Live Q/A
From CytoDyn Inc.
Via Business Wire
News headline image
Group of CytoDyn Stockholders Shares Strategic Plan to Obtain Cancer Therapy Approval for Leronlimab
From Gasthalter & Co. on behalf of CytoDyn Inc. shareholders
Via Business Wire
News headline image
CytoDyn Receives Clearance from Brazil’s FDA (ANVISA) to Commence a Pivotal Phase 3 Trial in Critically Ill COVID-19 Patients with IV Administration of Four Doses (700mg/week)
From CytoDyn Inc.
Via Business Wire
News headline image
CytoDyn’s Chairman, CMO, and Head of Business Development Dr. Scott A. Kelly to Present at the World Antiviral Congress 2021
From CytoDyn Inc.
Via Business Wire
Accelerated Development of COVID-19 Vaccines to Combat Potential for Possible Future Viral Pathogens and Variants
Via FinancialNewsMedia
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.